A Phase 3, Randomized, Double-Blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy

Trial Profile

A Phase 3, Randomized, Double-Blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Nusinersen (Primary)
  • Indications Spinal muscular atrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAR
  • Sponsors Biogen; Ionis Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2017 According to a Biogen Canada media release, the Health Canada has approved SPINRAZA (nusinersen) for the treatment of patients with 5q spinal muscular atrophy (SMA) based on data from this and multiple open-label trials.
    • 01 Jun 2017 According to an Ionis Pharmaceuticals media release, based on the data from ENDEAR and CHERISH trials,including results from open label studies in pre-symptomatic and symptomatic individuals with, or most likely to develop, Types 1, 2 or 3 SMA ,the European Commission (EC) has granted marketing authorization for SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA).
    • 28 Apr 2017 Study design and initial interim efficacy and safety findings, results presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top